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Abstract
Aim/hypothesis A strong association between susceptibility
to type 2 diabetes and common variants of transcription
factor 7-like 2 (TCF7L2), encoding an enteroendocrine
transcription factor involved in glucose homeostasis, has
been reported in three different populations (Iceland,
Denmark and USA) by Grant et al. We aimed to replicate
these findings in a Dutch cohort.
Methods We analysed the genotypes of two intronic single
nucleotide polymorphisms (SNPs) in TCF7L2 gene in 502
unrelated type 2 diabetes patients and in a set of healthy
controls (n=920). The two SNPs showed almost complete
linkage disequilibrium (D′=0.91).
Results We were able to replicate the previously reported
association in our Breda cohort. The minor alleles of
both variants were significantly over-represented in cases
(odds ratio [OR] 1.29, 95% CI 1.09–1.52, p ¼ 3 103 for
rs12255372; OR 1.41, 95% CI 1.19–1.66, p ¼ 4:4 105
for rs7903146). In addition, TCF7L2 haplotypes were
analysed for association with the disease. The analysis of
haplotypes did not reveal any strong association beyond
that expected from analysing individual SNPs. The TT
haplotype carrying the minor alleles was more frequent
among cases (OR 1.38, p ¼ 2:7 103).
Conclusions/interpretation Our data strongly confirm that
variants of the TCF7L2 gene contribute to the risk of type 2
diabetes. The population-attributable risk from this factor in
the Dutch type 2 diabetes population is 10%.
Keywords Association . Genetics . SNP. Susceptibility .
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TCF7L2 transcription factor 7-like 2
Introduction
The TCF7L2 gene encodes for an enteroendocrine tran-
scription factor that has a role in the Wnt signaling
pathway, which is one of the key developmental and
growth regulatory mechanisms of the cell. One of the
peptide hormones produced by enteroendocrine cells and
transcriptionally regulated by TCF7L2 is glucagon-like
peptide 1 (GLP-1). Hence, variants of the TCF7L2 gene
could influence the susceptibility to type 2 diabetes by
altering levels of the insulinotropic hormone GLP-1. In
concert with insulin, GLP-1 exerts a critical effect on blood
glucose homeostasis by stimulating early insulin production
from the pancreatic beta cells [1].
Recently, Reynisdottir et al. [2] found suggestive linkage
of type 2 diabetes to chromosome 10q in the Icelandic
population. Fine-mapping with 228 microsatellite markers
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in Icelandic individuals with type 2 diabetes and controls
throughout a 10.5 Mb interval on 10q identified one
microsatellite marker, DG10S478 in intron 3 of the
TCF7L2 gene, as being strongly associated with type 2
diabetes (p ¼ 2:1 109) [3]. This association was repli-
cated in both a Danish cohort (p ¼ 4:8 103) and a US
cohort (p ¼ 3:3 109). A combined analysis showed that
individuals heterozygous for the risk allele (38% of the
population) have a modest risk of 1.45 of developing type 2
diabetes, whereas individuals homozygous for the risk
allele (7% of the population) have a higher risk (2.41) of
developing type 2 diabetes.
In the current study we examined whether variants of the
TCF7L2 gene contribute to the risk of type 2 diabetes in a
Dutch population, using 502 unrelated type 2 diabetes
patients from the Breda cohort and a set of 920 healthy
controls.
Subjects and methods
Breda cohort DNA was available from 502 subjects with
type 2 diabetes from the Breda cohort (Table 1) [4]. All
patients were diagnosed according to the WHO criteria
(random plasma glucose levels >11.1 mmol/l or a fasting
plasma glucose level >7.0 mmol/l). The clinical character-
istics of the patients (HbA1c, plasma cholesterol, HDL-
cholesterol and triacyglycerol) were available, as well as the
level of obesity in each individual given by the BMI
(defined as weight [in kg] divided by height [in m]
squared). The control cohort (n=920) was comprised of
healthy blood bank donors of white Dutch origin [5].
Informed written consent was obtained from all individuals.
The Breda study was approved by the Medical Ethics
Committee of the University Medical Center Utrecht.
Genotyping SNPs were genotyped using Taqman assay-on-
demand (Applied Biosystems). Assays were performed
according to the manufacturer’s specifications (assays
C_29347861_10, C_291484_20). The sequence informa-
tion for all primers and probes is available upon request.
The genotypes were analysed using a TaqMan 7900HT
(Applied Biosystems, Nieuwerkerk a/d IJssel, the Nether-
lands). The DNA samples were processed in 384-well
plates. Each plate contained eight negative controls and 16
genotyping controls (four duplicates of four different
samples obtained from the Centre d’Etude du Polymor-
phisme Humain [CEPH]). The genotype success rates were
97.8% for rs12255372 and 98.6% for rs7903146. There
were no discordances in the genotypes of any of the CEPH
samples. The controls were in agreement with Hardy–
Weinberg equilibrium (χ2=2.72, p=0.10 for rs12255372
and χ2=0.72, p=0.40 for rs7903146).
Statistical analysis The genotype frequencies were tested
for Hardy–Weinberg equilibrium by χ2 analysis. Differ-
ences in allele, genotype and haplotype distribution in case
and control subjects were tested for significance using a
95% two-sided χ2 test. Odds ratios (ORs) and CIs were
calculated using Woolf’s method with Haldane’s correction
[6]. To test for association of genotypes and type 2 diabetes,
genotype-based ORs with 95% CIs were calculated using
logistic regression model, where individuals homozygous
for the common allele were the reference group. The
association between genotypes of two SNPs and the
cohort’s clinical characteristics and BMI was determined
using linear regression analysis, including age and sex as
explanatory variables in the models. Haplotypes of two
polymorphisms were estimated using the COCAPHASE
package of UNPHASED program [7]. The D′ and r2
between the TCF7L2 SNPs were calculated with the same
package. Population attributable risk (PAR) was calculated
for rs7903146 using the corresponding genotype frequen-
cies for this marker as explained by Greenland et al. [8].
Power calculation was completed using the UCLA’s
Department of Statistics Power Calculator (available at
http://www.calculators.stat.ucla.edu/powercalc). All statisti-
cal analyses were performed using SPSS program, version
13.0 for Windows (SPSS, Chicago, IL, USA) unless
otherwise stated.
Results
We genotyped two SNPs (rs12255372, rs7903146) that were
shown to be most strongly associated with type 2 diabetes by
Grant et al. [3]. Their study showed that the rs12255372*T
allele is perfectly correlated with the DG10S478 risk
Table 1 Descriptive statistics for study subjects from the type 2
diabetes Breda cohort and the control cohort
Trait Breda cohort Control cohort
n (female/male) 502 (272/229a) 920 (354/557b)
Age-at-study (years) 70.8±9.9 47.8±12.7
Age-at-diagnosis (years) 63.0±11.3 –
BMI (kg/m2) 27.8±4.1 NA
HbA1c (%) 7.3±1.1 NA
HDL-cholesterol (mmol/l) 1.2±0.3 NA
Total cholesterol (mmol/l) 5.3±1.0 NA
Triacylglycerol (mmol/l) 1.9±1.0 NA
The data are presented as mean±SD
HbA1c, haemoglobin A1c (glucose bound to haemoglobin); NA, not
available
a Not available for one subject; b not available for nine subjects
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allele. The rs12255372 variant was successfully geno-
typed in 492 individuals from the Breda cohort and in
901 controls. The T allele was significantly more frequent
in patients than controls (34 vs 29%, p=0.003), and the
frequencies of the GT and minor TT genotypes were also
increased in type 2 diabetes patients (p=0.012) (Table 2).
However, this association was weaker than that observed
with rs7903146.
The variant rs7903146 in the TCF7L2 gene could be
genotyped in 496 case and 907 control subjects. The T
allele was over-represented in the type 2 diabetes cohort
compared with the control group (37 vs 29%, p=4.4×10−5)
(Table 2), which is compatible with the results of Grant et
al. The CT and TT genotypes were more prevalent in the
type 2 diabetes patients with a frequency of 45% and 15%
in cases, respectively, compared with a frequency of 40% of
CT genotype and 9% of TT genotype in control subject
(p=0.0003).
Risks were consistently higher for homozygous than for
heterozygous persons for both SNPs (OR 1.53, 95% CI
1.05–2.21 and OR 1.35, 95% CI 1.07–1.71 for rs12255372
and OR 1.96, 95% CI 1.37–2.80 and OR 1.37, 95% CI
1.08–1.73 for rs7903146, respectively) (Table 2). More-
over, the test for trend showed even stronger association of
the disease with an increased number of minor alleles,
especially for rs7903146 (p=6.6×10−5), suggesting an
allele–dose effect.
The two SNPs were found to be in strong LD with each
other (D′=0.91, r2=0.76) in our control population. The TT
haplotype, which carries the two minor alleles of both
SNPs, was more common among patients than controls (33
vs 26%, p=0.00027). As the haplotype does not perform
better than the rs7903146 SNP located in intron 3 of
TCF7L2, this SNP can be used as a marker for type 2
diabetes risk. The allele frequency data for rs7903146
revealed that individuals carrying the T allele (37%
frequency in patients compared with 29% in control
subjects) have a modest but significantly higher risk of
developing type 2 diabetes (OR 1.41, 95% CI 1.19–1.66),
with a population attributable risk of 10% (95% CI 0.054–
0.155). These results strongly suggest that TCF7L2 is
associated with type 2 diabetes in the Dutch Breda cohort.
Discussion
Recently Grant et al. [3] demonstrated a convincing
association between susceptibility to type 2 diabetes and
common variants in TCF7L2. In order to replicate these
findings, two TCF7L2 SNPs (rs12255372 and rs7903146)
were genotyped in the Dutch Breda cohort and a control
group. Our study had power of 80% at p=0.05 to detect
effects with an OR >1.39 for the examined variants.
Consistent with the observation of Grant et al., we found
the minor alleles of both variants were significantly over-
represented in Dutch type 2 diabetes patients. The frequen-
cy of heterozygous and homozygous carriers of the at-risk
alleles, compared with non-carriers, was also increased in
type 2 diabetes patients. In line with Grant et al., we also
revealed a negative, borderline-significant association with
BMI (data not shown), suggesting that BMI does not
influence the risk variants.
Despite serious efforts to identify genetic variants that
predispose to common forms of type 2 diabetes, till now
only a few genes, such as KCNJ11, PPARG and HNF4A
have been reproducibly associated with this complex
disease in a variety of large-scale studies performed in the
different populations [9, 10]. Our replication study shows
that the TCF7L2 gene is an important candidate gene
contributing to susceptibility to type 2 diabetes. Since the
most strongly associated SNP is within an intron of the
TCF7L2 gene, this SNP is not likely to be the true disease
variant. However, the intronic variants may affect the level
of gene expression by altering, for example, transcription,
Table 2 Comparison of geno-
type and allele frequencies in
the Breda cohort and control
subjects
T2D, type 2 diabetes
Genotype T2D patients (n=502) Control subjects (n=920) OR 95% CI p value
rs12255372
GG (%) 216 (44) 469 (52) – – –
GT (%) 217 (44) 348 (39) 1.35 1.07–1.71 0.01
TT (%) 59 (12) 84 (9) 1.53 1.05–2.21 0.03
p value genotype 0.012
G allele (%) 649 (66) 1286 (71)
T allele (%) 335 (34) 516 (29) 1.29 1.09–1.52 0.003
rs7903146
CC (%) 203 (41) 459 (51) – – –
CT (%) 221 (45) 365 (40) 1.37 1.08–1.73 0.009
TT (%) 72 (15) 83 (9) 1.96 1.37–2.80 0.0002
p value genotype 0.0003
C allele (%) 627 (63) 1283 (71)
T allele (%) 365 (37) 531 (29) 1.41 1.19–1.66 0.00004
Diabetologia (2007) 50:59–62 61
splicing or message stability. Hence, full sequence analysis
of the gene and a comparison of the allelic architecture
among different type 2 diabetes populations are needed to
identify the causative variant. The TCF7L2 gene probably
contributes to the complex nature of type 2 diabetes by
affecting the blood glucose homeostasis, since TCF7L2 is
known to control the activity of a number of genes,
including the proglucagon gene that encodes the insulino-
tropic hormone GLP-1. GLP-1, along with insulin, plays a
role in blood glucose homeostasis, and GLP-1 therapies for
type 2 diabetes are currently in clinical development. As
long as the exact role of these gene polymorphisms remains
unclear, it is difficult to assess its functional role in the
development of type 2 diabetes.
It will be of great interest to learn the molecular mechanisms
of action of the TCF7L2 gene in the pathogenesis of type 2
diabetes and to identify potential targets for drugs that could
be used for treatment and prevention of the disease due to the
gene variants. It is tempting to speculate on a future genetic
test that could identify the individuals carrying the at-risk
TCF7L2 gene variants, so that they could be offered a
preventive healthcare programme (special diet and exercises).
In conclusion, we have confirmed that variants of the
TCF7L2 gene modulate susceptibility to type 2 diabetes in
a Dutch population.
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